Victoria Klesty | Reuters
Wegovy, a popular weight loss treatment, has now been approved for heart health in the U.S. This approval, however, may not immediately lead to broader insurance coverage due to concerns about its high monthly cost of $1,350. Some employers and health plans are hesitant to cover the drug, citing budget constraints and uncertainty about patient adherence to the treatment. Despite this, insurance industry experts believe that the approval may prompt some plans to reconsider coverage in the future. As a result, Americans seeking Wegovy treatment may face a varied and complex system of insurance coverage.
2024-03-16 06:00:01
Post from www.cnbc.com